Aurinia Pharmaceuticals Inc.

NasdaqGM AUPH

Aurinia Pharmaceuticals Inc. Shareholders' Equity for the year ending December 31, 2023: USD 377.95 M

Aurinia Pharmaceuticals Inc. Shareholders' Equity is USD 377.95 M for the year ending December 31, 2023, a -6.78% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Aurinia Pharmaceuticals Inc. Shareholders' Equity for the year ending December 31, 2022 was USD 405.44 M, a -15.37% change year over year.
Aurinia Pharmaceuticals Inc. Shareholders' Equity for the year ending December 31, 2021 was USD 479.09 M, a 17.50% change year over year.
Aurinia Pharmaceuticals Inc. Shareholders' Equity for the year ending December 31, 2020 was USD 407.75 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGM: AUPH

Aurinia Pharmaceuticals Inc.

CEO	Mr. Peter S. Greenleaf M.B.A.
IPO Date	Sept. 3, 2014
Location	Canada
Headquarters	4464 Markham Street
Employees	300
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Vaccines

Description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Key trends

Past 5 years